Mineralys Q3 Loss Widens to $57.3M as Launch Spending Builds; $624.7M Cash
MLYS is trading near its 52-week low of $15.33 (9.7% above the low).
Summary
Mineralys posted a $57.3M Q3 loss as commercialization spending ramped, with $624.7M in cash and investments ahead of the December 22, 2026 FDA decision on lorundrostat.
Key Events · Earnings and Guidance · MLYS
-
Q3 Loss Widens on Launch Spending
Net loss of $57.3M ($0.64 per share) versus $36.9M ($0.52) in Q3 2025. G&A rose to $37.4M from $9.7M on commercialization headcount and professional fees, while R&D fell $8.8M to $22.7M as the pivotal program concluded.
-
Cash Covers Launch; Debt Tied to Approval
Cash, cash equivalents and investments totaled $624.7M at September 30, 2026, with $187.2M still available under the ATM and $400M of undrawn term-loan tranches. The $150M Tranche B draw requires FDA approval of the lorundrostat NDA; if not met by September 30, 2027, four $25M quarterly repayments begin and maturity accelerates to June 30, 2028.
-
Tanabe License Terminated, Patents Owned
The October 27, 2026 termination assigns all lorundrostat IP rights to Mineralys with no material penalty, but up to $255.0M of commercial milestones remain payable, plus up to $10.0M for a second indication.
-
FDA Decision Due December 22, 2026
The lorundrostat NDA for hypertension has a PDUFA target date of December 22, 2026; the company is staffing commercial functions in anticipation of approval.
Analysis · MLYS · Life Sciences
The quarterly loss widened to $57.3M from $36.9M a year ago, driven almost entirely by the pre-commercial build-out: G&A jumped to $37.4M from $9.7M as the company staffs sales, market access and medical affairs ahead of the December 22, 2026 FDA decision on lorundrostat. R&D actually fell $8.8M as the pivotal program wound down. With $624.7M in cash and investments, plus $187.2M still available under the ATM and $400M of undrawn term-loan tranches, funding through launch is not in question — but the burn rate is now the number that matters, and the Tranche B $150M draw is contingent on FDA approval. The 10-Q also confirms the October 27 Tanabe termination that hands Mineralys direct ownership of the lorundrostat patents while leaving up to $255M of commercial milestones payable.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLYS was trading at $16.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $15.33 to $47.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.